VIJAYAKUMAR THANGAVEL MAHALINGAM

Dr. VIJAYAKUMAR THANGAVEL MAHALINGAM


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2014 in Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
VMVIJAYAKUMAR THANGAVEL MAHALINGAM
VIJAYAKUMAR THANGAVEL MAHALINGAM
RKRamasamy Mohan Kumar
Ramasamy Mohan Kumar
AAAruna Agrawal
Aruna Agrawal
GDGovind Prasad Dubey
Govind Prasad Dubey
IKILANGO KALIAPPAN
ILANGO KALIAPPAN

1 January 2017 in Current Therapeutic Research
Verified
Journal Article
Open access
VMVIJAYAKUMAR THANGAVEL MAHALINGAM
VIJAYAKUMAR THANGAVEL MAHALINGAM
JJJayasutha Jayram
Jayasutha Jayram
VCVishnu Meghana Cheekireddy
Vishnu Meghana Cheekireddy
DHDasari Himaja
Dasari Himaja
YTYalamanchili Dharma Teja
Yalamanchili Dharma Teja
DNDamodharan Narayanasamy
Damodharan Narayanasamy
Type 2 diabetes mellitus (T2DM) is a multifactorial disease characterized by insulin resistance. As time progresses, monotherapy often does not provide effective glycemic control, generating the need for an add-on therapy. Hence, multiple oral hypoglycemic agents formulated as a single-dose form called fixed-dose combinations (FDCs) play an essential role in glycemic control. The purpose of this systematic review is to appraise the recently published evidence on the safety, efficacy, and bioavailability of FDCs. A comprehensive literature search of PUBMED, Scopus, ScienceDirect.com, ProQuest, SpringerLink, clintrials.gov, Embase, and EBSCO using the key words FDCs, combination therapy, T2DM management, and add-on therapy was conducted. Studies on the safety profile/tolerability, efficacy, and bioavailability of various FDCs of oral hypoglycemic agents were preferred. The systematic review of all the publications suggests that FDCs of oral hypoglycemic agents (OHAs) significantly reduce HbA1c and fasting plasma glucose values, thereby efficiently reducing hyperglycemia in patients in whom monotherapy fails. FDCs are the bioequivalent of the concomitant drugs administered as individual components. Improved adherence to FDCs and the absence of serious adverse drug reactions compared with dual therapy play an important role in decreasing the incidence of hyperglycemia in patients with T2DM. From this updated review, it was found that metformin was the most widely used component of FDCs with other OHAs. Studies on the safety and efficacy of newly approved OHAs such as sodium glucose cotransporter inhibitors were limited. An increasing number of randomized trials on the safety and efficacy of newly emerging FDCs suggests that they would be better treatment options for T2DM patients.

18 June 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NSN. Sai Supra Siddhu
N. Sai Supra Siddhu
AGAjay Guru
Ajay Guru
RKRajappan Chandra Satish Kumar
Rajappan Chandra Satish Kumar
BABader Almutairi
Bader Almutairi
MAMikhlid Hammad Almutairi
Mikhlid Hammad Almutairi
JAJesu Arockiaraj
Jesu Arockiaraj

1 January 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
NRN.A. Rajesh
N.A. Rajesh
LDL. Drishya
L. Drishya
MAMurali Mohan Raju Ambati
Murali Mohan Raju Ambati
ANAthi L. Narayanan
Athi L. Narayanan
MAMaria Alex
Maria Alex
VMVIJAYAKUMAR THANGAVEL MAHALINGAM
VIJAYAKUMAR THANGAVEL MAHALINGAM

1 January 2019 in Current Therapeutic Research
Verified
Journal Article
Open access
KRKiran Kumar Rathinam
Kiran Kumar Rathinam
JAJustin Jacob Abraham
Justin Jacob Abraham
VMVIJAYAKUMAR THANGAVEL MAHALINGAM
VIJAYAKUMAR THANGAVEL MAHALINGAM
Asthma affects millions of patients across the globe and also accounts for numerous mortalities every year. The current pharmacologic approach to the treatment of asthma includes the use of glucocorticoids and beta-agonists mainly. However, these conventional therapies have poor controllability of moderate-to-severe asthma and also produce several side effects on their long-term use. These limitations had led to the development of biologics targeting the mediators involved in T helper 2-inflammation associated with the pathogenesis of asthma such as interleukin (IL) 4, IL-5, and IL-13. dupilumab, a fully human monoclonal antibody, an IL-4 receptor alpha-antagonist targeting IL-13 and IL-4 has a potential role in treatment of moderate-to-severe asthma and was approved by the Food and Drug Administration on October 19, 2018. The dual-antagonistic action of dupilumab on IL-4 and IL-13 receptors renders it more efficient in asthma treatment. To review the efficacy and safety profile of dupilumab in the treatment of moderate-to-severe asthma. Systematic search was performed via PubMed, Cochrane library, Embase, and ClinicalTrials.gov using the key words dupilumab, moderate-to-severe asthma, interleukin, IL-13, IL-4, and monoclonal antibody. Randomized controlled trials that compared between placebo and dupilumab in patients with uncontrolled asthma were included and observational studies were excluded in this review. The review of selected literature reveals that addition of dupilumab to conventional therapy improves forced expiratory volume in 1 second and reduces the risk of severe asthma exacerbations in patients. No significant differences in incidence of adverse drug reactions/adverse drug events were observed between dupilumab and placebo groups except higher rates of injection site reactions in the dupilumab group. Concomitant use of dupilumab with long-acting beta agonists used in combination with inhaled corticosteroids, improves clinical outcomes and quality of life in patients with moderate to severe asthma. Although dupilumab has a promising role in treatment of patients with asthma, it is still in the emerging stage for its acceptance globally. Ongoing studies will help to determine dupilumab's long-term efficacy and safety for its future extensive use.

9 April 2014 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MGMelvin George
Melvin George
MRMuthukumar Rajaram
Muthukumar Rajaram
ESElangovan Shanmugam
Elangovan Shanmugam
VMVIJAYAKUMAR THANGAVEL MAHALINGAM
VIJAYAKUMAR THANGAVEL MAHALINGAM